Press releaseGlobe Newswire
Reviva Pharmaceuticals Holdings
RVPH · NASDAQ
$0.46+$0.01 (+2.22%)TodayMarket closed ·
Prev close $0.45
Latest news
- Press releaseGlobe Newswire
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Press releaseGlobe Newswire
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
- Press releaseGlobe Newswire
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Dow Falls 200 Points; US Producer Prices Surge In April
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsSweta Killa
Robert F. Kennedy Jr. Wants To Take 'Clear And Decisive Action' On Psychiatric Drugs Amid 'Deprescribing' Push: Big Pharma Should Pay Attention
- Press releaseGlobe Newswire
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric Indications
- NewsCaroline Ryan
Deal Dispatch: Amazon Buys Globalstar, Instacart Grabs Instaleap, QVC Announces Bankruptcy
- Press releaseGlobe Newswire
Reviva Announces Letter to Shareholders
- Press releaseGlobe Newswire
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAlex Perry
What's Behind The Drop In Reviva Pharmaceuticals Stock?
- NewsAvi Kapoor
Gold Tumbles Over 6%; Accenture Earnings Top Views
- NewsAvi Kapoor
Dow Falls Over 300 Points; US Initial Jobless Claims Fall
- NewsAvi Kapoor
Why Five Below Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
- NewsAvi Kapoor
Dow Gains 100 Points; US Durable Goods Orders Decline In October
- NewsAvi Kapoor
US Stocks Mixed; GDP Growth Tops Expectations
- NewsVandana Singh
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Why Actelis Networks Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
- NewsAvi Kapoor
Crude Oil Down 1%; Lennar Earnings Miss Views
- NewsAvi Kapoor
Nasdaq Gains 100 Points; FedEx Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Crude Oil Gains Over 1%; Walgreens Posts Upbeat Earnings
- NewsAvi Kapoor
Dow Surges 200 Points; US GDP Contracts 0.5%
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Spotify To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.